The Biogen-backed Duchenne muscular dystrophy drug developer saw its share price rise sharply after securing approximately $125m in its IPO.
Solid Biosciences, a US-based Duchenne muscular dystrophy (DMD) therapy developer backed by neurological disease drug producer Biogen, has raised almost $125m in its initial public offering.
The company issued approximately 7.81 million shares on the Nasdaq Global Select Market priced at $16.00 each, below the IPO range of $18 to $19, though the number of shares in the offering was increased from 7 million.
Solid Bio is working on a treatment for DMD, a genetic muscle-wasting disease that generally affects…
